Putamen Atrophy Is a Possible Clinical Evaluation Index for Parkinson’s Disease Using Human Brain Magnetic Resonance Imaging

Abstract

Parkinson’s disease is characterized by motor dysfunction caused by functional deterioration of the substantia nigra. Lower putamen volume (i.e., putamen atrophy) may be an important clinical indicator of motor dysfunction and neurological symptoms, such as autonomic dysfunction, in patients with Parkinson’s disease. We proposed and applied a new evaluation method for putamen volume measurement on 31 high-resolution T2-weighted magnetic resonance images from 16 patients with Parkinson’s disease (age, 80.3 ± 7.30 years; seven men, nine women) and 30 such images from 19 control participants (age, 75.1 ± 7.85 years; eleven men, eight women). Putamen atrophy was expressed using a ratio based on the thalamus. The obtained values were used to assess differences between the groups using the Wilcoxon rank-sum test. The intraclass correlation coefficient showed sufficient intra-rater reliability and validity of this method. The Parkinson’s disease group had a significantly lower mean change ratio in the putamen (0.633) than the control group (0.719), suggesting that putamen atrophy may be identified using two-dimensional images. The evaluation method presented in this study may indicate the appearance of motor dysfunction and cognitive decline and could serve as a clinical evaluation index for Parkinson’s disease.